Maxim Group analyst Naz Rahman maintained a Buy rating on PainReform (PRFX – Research Report) yesterday and set a price target of $3.00. The company’s shares opened today at $0.65.
Rahman covers the Healthcare sector, focusing on stocks such as Clene, Viking Therapeutics, and Virpax Pharmaceuticals. According to TipRanks, Rahman has an average return of 2.6% and a 36.52% success rate on recommended stocks.
Currently, the analyst consensus on PainReform is a Moderate Buy with an average price target of $3.00.
See today’s best-performing stocks on TipRanks >>
PRFX market cap is currently $7.03M and has a P/E ratio of -0.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company’s product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Read More on PRFX:
- PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
- PainReform announces safety data in first part of Phase 3 trial of PRF-110
- PainReform completes 1st part of clinical trial for patients having bunionectomy
- PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery
- PainReform reports 2022 net loss $8.79M vs. $7.24M last year
